The estimated Net Worth of Robert James Wills is at least $560 Thousand dollars as of 8 April 2024. Robert Wills owns over 3,086 units of Cymabay Therapeutics Inc stock worth over $324,800 and over the last 10 years he sold CBAY stock worth over $8,859. In addition, he makes $225,993 as Independent Chairman of the Board at Cymabay Therapeutics Inc.
Sign up
Robert Wills CBAY stock SEC Form 4 insiders trading
Robert has made over 12 trades of the Cymabay Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 3,086 units of CBAY stock worth $27,651 on 8 April 2024.
The largest trade he's ever made was buying 100,000 units of Cymabay Therapeutics Inc stock on 16 June 2016 worth over $65,000. On average, Robert trades about 6,500 units every 74 days since 2015. As of 8 April 2024 he still owns at least 10,000 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Robert Wills stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Wills biography
Dr. Robert James Wills, Ph.D. is Independent Chairman of the Board of the Board of the Company. Dr. Wills was elected to the Board because of his over 35 years of extensive and significant experience in the pharmaceutical industry, including preclinical and clinical research and development, business development and strategic partnering. Dr. Wills served in a variety of executive roles for Johnson & Johnson, or J&J, a medical devices, pharmaceutical and consumer goods manufacturing company, from December 1989 to February 2015 and recently served as Vice President, Alliance Manager where he was responsible for managing strategic alliances for J&J’s Pharmaceutical Group worldwide since 2002. Prior to this, Dr. Wills spent 22 years in pharmaceutical drug development, 12 of which were at J&J and 10 of which were at Hoffmann-La Roche Inc. Before assuming his role as Vice President, Alliance Manager at J&J, Dr. Wills served as Senior Vice President Global Development at J&J where he was responsible for its late stage development pipeline and was a member of several internal commercial and research and development operating boards. Dr. Wills currently serves on the board of directors of Oncternal Therapeutics, Inc., Parion Sciences, Inc. and Go Therapeutics, Inc. Dr. Wills was previously a member of the board of directors of GTx, Inc., where he served as Executive Chairman and Chair of the Scientific and Development Committee. Dr. Wills holds a B.S. in Biochemistry and a M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas. Because of his more than 35 years of experience in the pharmaceutical industry as an executive focused on research and development, business development and strategic partnering, as well as his corporate governance and board oversight experience, we believe he is able to make valuable contributions to the Board.
What is the salary of Robert Wills?
As the Independent Chairman of the Board of Cymabay Therapeutics Inc, the total compensation of Robert Wills at Cymabay Therapeutics Inc is $225,993. There are 7 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.
How old is Robert Wills?
Robert Wills is 66, he's been the Independent Chairman of the Board of Cymabay Therapeutics Inc since 2015. There are no older and 15 younger executives at Cymabay Therapeutics Inc.
What's Robert Wills's mailing address?
Robert's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.
Insiders trading at Cymabay Therapeutics Inc
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, and Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
What does Cymabay Therapeutics Inc do?
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
What does Cymabay Therapeutics Inc's logo look like?
Complete history of Robert Wills stock trades at Cymabay Therapeutics Inc, Milestone Pharmaceuticals Inc, and Oncternal Therapeutics
Cymabay Therapeutics Inc executives and stock owners
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sujal Shah,
President, Chief Executive Officer, Director -
Charles McWherter,
Senior Vice President, Chief Scientific Officer -
Klara Dickinson,
Chief Regulatory and Compliance Officer -
Daniel Menold,
Vice President - Finance -
Sujal A. Shah,
Pres, CEO & Director -
Dr. Charles A. McWherter Ph.D.,
Chief Scientific Officer -
Paul T. Quinlan,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Robert Wills,
Independent Chairman of the Board -
Kurt von Emster,
Independent Director -
Paul Truex,
Independent Director -
Caroline Loewy,
Independent Director -
Dr. Dennis D. Kim M.B.A., M.D., MBA,
Chief Medical Officer -
Becki Filice,
Sr. VP of Portfolio & Product Leadership -
Klara A. Dickinson-Eason,
Chief Regulatory & Quality Assurance Officer -
Dr. Robert L. Martin,
Sr. VP of Manufacturing & Nonclinical Devel. -
Patrick J. O'Mara,
Sr. VP of Bus. Devel. -
Ken Boehm,
Sr. VP of HR -
Daniel Menold,
VP of Fin. -
Evan A. Stein,
Director -
Robert F. Booth,
Director -
Carl Goldfischer,
Director -
Pol F Boudes,
Chief Medical Officer -
Robert J. Weiland,
Director -
Kirk Rosemark,
V.P. Regulatory & Quality -
Wart Harold Van,
President and CEO -
Emster Kurt Von,
Director -
Thomas G Wiggans,
-
Paul T Quinlan,
General Counsel -
Eric Lefebvre,
-
Harish Shantharam,
Chief Financial Officer -
Lewis J Stuart,
Chief Commercial Officer -
Patrick J. O Mara,
VP, Business Development -
Robert L. Martin,
Sr. Vice President -
Capital Advisors Llc Aghaza...,
-
Edward Penhoet,
Director -
Louis G Lange,
Director -
Hari Kumar,
Director -
Janet Dorling,
-
Dennis D Kim,
Chief Medical Officer